Treatment of Chronic Delta Hepatitis: A Nine-Year Retrospective Analysis

Basit Öğe Kaydı
dc.contributor.authorGulsun, Serda
dc.contributor.authorTekin, Recep
dc.contributor.authorBozkurt, Fatma
dc.date.accessioned2024-04-24T17:28:05Z
dc.date.available2024-04-24T17:28:05Z
dc.date.issued2011
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: Chronic delta hepatitis is the most severe form of viral hepatitis, for which interferon administration is the only available treatment. However, the efficacy of interferon treatment is affected by the dose and duration of treatment, and relapse rates are high. Objectives: In this study, we sought to evaluate the efficacy of treatment with pegylated interferon and observe the relapse rates of delta hepatitis after treatment. Patients and Methods: Forty-six patients with chronic delta hepatitis were retrospectively studied between January 2002 and December 2010. Patients were evaluated for biochemical, virological, and histological responses. They were then followed-up for at least 1 year after discontinuation of the treatment. Results: All the 46 patients in the study received PEG-IFN therapy. Of the 46 patients, 25 were treated with PEG-IFN for 1 year and 21 were treated for 2 years. Sixteen patients (34.7%) showed a biochemical response, 27 (58.6%) showed a virological response, and 39 (84.7%) showed a histological response. Sustained virological and biochemical responses were achieved in 41% and 47.8% of the patients, respectively. Sixteen (84.2%) patients of the 19 with high levels of hepatitis delta virus RNA (HDV RNA) (HDV RNA level >1 x 105) and 10 (71.4%) of the 14 patients with high titers of hepatitis B surface antigen (HbsAg) (HbsAg > 102 IU/mL) at the beginning of the treatment showed relapse after treatment. Conclusions: We found no significant differences between 1-year and 2-year treatments. However, the relapse rate was lower in the 2-year treatment group. Higher HDV RNA and HbsAg levels before treatment were associated with higher relapse rates. Younger age was a significant factor in predicting response. (C) 2011 Kowsar M.P.Co. All rights reserved.en_US
dc.identifier.doi10.5812/kowsar.1735143X.2462
dc.identifier.endpage735en_US
dc.identifier.issn1735-143X
dc.identifier.issn1735-3408
dc.identifier.issue9en_US
dc.identifier.pmid22235216
dc.identifier.scopus2-s2.0-80053646100
dc.identifier.scopusqualityQ3
dc.identifier.startpage731en_US
dc.identifier.urihttps://doi.org/10.5812/kowsar.1735143X.2462
dc.identifier.urihttps://hdl.handle.net/11468/20317
dc.identifier.volume11en_US
dc.identifier.wosWOS:000295902200007
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherKowsar Publen_US
dc.relation.ispartofHepatitis Monthly
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChronic Delta Hepatitisen_US
dc.subjectPegylated Interferonen_US
dc.subjectTreatmenten_US
dc.titleTreatment of Chronic Delta Hepatitis: A Nine-Year Retrospective Analysisen_US
dc.titleTreatment of Chronic Delta Hepatitis: A Nine-Year Retrospective Analysis
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu